| 1491P bespoke circulating tumor DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients E Ococks, A Ng, G Devonshire, S Dashner, WC Chan, S Sharma, HT Wu, ... Annals of Oncology 31, S926, 2020 | 1 | 2020 |
| 1762P Association of clonal hematopoiesis of indeterminate potential with higher risk of disease progression D Klarin, E Kalashnikova, HT Wu, S Mehta, R Salari, H Sethi, ... Annals of Oncology 32, S1212, 2021 | | 2021 |
| 370P Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients E Ococks, A Ng, G Devonshire, S Dashner, WC Chan, S Sharma, HT Wu, ... Annals of Oncology 31, S1317-S1318, 2020 | | 2020 |
| 420P Minimal residual disease detection and tracking tumour evolution using ctDNA in stage I-III colorectal cancer patients TV Henriksen, N Tarazona, T Reinert, JA Carbonell-Asins, D Roda, ... Annals of Oncology 31, S419-S420, 2020 | 2 | 2020 |
| A combinatorial algorithm to identify independent and recurrent copy number aberrations across cancer types HT Wu, I Hajirasouliha, BJ Raphael 2014 IEEE 4th International Conference on Computational Advances in Bio and …, 2014 | 2 | 2014 |
| A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes JJ Gruber, A Afghahi, K Timms, A DeWees, W Gross, VN Aushev, HT Wu, ... Nature Cancer 3 (10), 1181-1191, 2022 | 54 | 2022 |
| A phase II study of talazoparib monotherapy in patients with wild‑type BRCA1 and BRCA2 with a mutation in other homologous recombina‑tion genes. Nat Cancer. 2022; 3 (10): 1181–91 JJ Gruber, A Afghahi, K Timms, A DeWees, W Gross, VN Aushev, HT Wu, ... DOI: https://doi. org/10.1038/s43018-022-00439-1. PMID: https://www. ncbi …, 0 | 5 | |
| Abstract A30: miRNA Regulators of Ovarian Cancer Metastasis that Predict Patient Outcomes AS Brodsky, HT Wu, S Vang, B Raphael, L Brard Cancer Research 72 (2_Supplement), A30-A30, 2012 | | 2012 |
| Abstract C119: Somatic and germline heterogeneity across colorectal cancer patient characteristics: Implications for early cancer detection P Srinivasan, B Gutman, SL Bristow, HT Wu, R Salari, R Swenerton, ... Cancer Epidemiology, Biomarkers & Prevention 32 (12_Supplement), C119-C119, 2023 | | 2023 |
| Abstract LB111: Comparison of the predictive and prognostic significance of circulating tumor DNA in patients with high risk HER2-negative breast cancer receiving neoadjuvant … MJM Magbanua, LB Swigart, D Renner, S Shchegrova, GL Hirst, C Yau, ... Cancer Research 82 (12_Supplement), LB111-LB111, 2022 | | 2022 |
| Abstract P040: Mutational heterogeneity of colorectal cancers across ancestries and its implications for cancer early detection P Srinivasan, B Gutman, V Aushev, S Sharma, T Arbel, HT Wu, ... Cancer Prevention Research 16 (1_Supplement), P040-P040, 2023 | | 2023 |
| Abstract P2-01-06: Detection of circulating tumor DNA post neoadjuvant chemotherapy using a personalized assay is associated with disease relapse E Agostinetto, F Cailleux, M Lambertini, F Rothé, HT Wu, M Balcioglu, ... Cancer Research 82 (4_Supplement), P2-01-06-P2-01-06, 2022 | 1 | 2022 |
| Abstract P2-01-10: Detection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgery I Garcia-Murillas, RJ Cutts, L Ulrich, M Beaney, M Robert, M Coakley, ... Cancer Research 82 (4_Supplement), P2-01-10-P2-01-10, 2022 | 2 | 2022 |
| Abstract P5-01-04: Personalized monitoring of circulating tumor DNA during neoadjuvant therapy in high-risk early stage breast cancer reflects response and risk of metastatic … MJM Magbanua, L Brown-Swigart, G Hirst, C Yau, D Wolf, HT Wu, A Tin, ... Cancer Research 80 (4_Supplement), P5-01-04-P5-01-04, 2020 | 1 | 2020 |
| Abstract PD9-02: Personalized ctDNA as a predictive biomarker in high-risk early stage breast cancer (EBC) treated with neoadjuvant chemotherapy (NAC) with or without … MJM Magbanua, D Wolf, D Renner, S Shchegrova, LB Swigart, C Yau, ... Cancer Research 81 (4_Supplement), PD9-02-PD9-02, 2021 | 8 | 2021 |
| An integrative probabilistic model for identification of structural variation in sequencing data SS Sindi, S Önal, LC Peng, HT Wu, BJ Raphael Genome biology 13, 1-25, 2012 | 176 | 2012 |
| An online literature mining tool for protein phosphorylation X Yuan, ZZ Hu, HT Wu, M Torii, M Narayanaswamy, KE Ravikumar, ... Bioinformatics 22 (13), 1668-1669, 2006 | 38 | 2006 |
| Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer T Reinert, TV Henriksen, E Christensen, S Sharma, R Salari, H Sethi, ... JAMA oncology 5 (8), 1124-1131, 2019 | 678 | 2019 |
| Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P) C Yang, MA Iafolla, S Dashner, W Xu, AR Hansen, P Bedard, S Lheureux, ... Annals of Oncology 30, v34, 2019 | 3 | 2019 |
| Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P) MAJ Iafolla, C Yang, S Dashner, W Xu, AR Hansen, PL Bedard, ... J Clin Oncol 37 (15_suppl), 2542-2542, 2019 | 7 | 2019 |
Ben RaphaelProfessor of Computer Science, Princeton UniversityVerified email at princeton.edu